Medipal Holdings (7459) · InitiativeFirst stated

Clinical-Trial Distribution for Cardiac Muscle Regenerative Medicine Through a Capital and Business Alliance with Heartseed

First written in FY2020. . Latest entry: FY2020.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Regenerative Medicine Product Transport Management and Logistics Network BusinessA theme 2 companies write about · 0 as a headwind · 4 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2020First statedAnnual report
「In March 2020, we entered into a capital and business partnership with Heartseed Inc. (Shinjuku-ku, Tokyo; hereinafter, Heartseed), which is working to commercialize cardiac regenerative medicine at an early stage. In connection with this partnership, the Company, its consolidated subsidiary SPLiNE Corporation, and Heartseed began joint research on clinical trial distribution.」
In March 2020, the Company entered into a capital and business partnership with Heartseed and began joint research on clinical trial distribution for cardiac regenerative medicine with Medipal, SPLiNE, and Heartseed.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Medipal Holdings's next results are scheduled for 2026-11-05. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.